Chinese Premier Li Qiang, who delivered a keynote speech at the opening ceremony of CDF 2025, underscored China’s commitment ...
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The Milner Institute was the host for the official opening of the new Functional Genomics Screening Laboratory (FGSL). Key ...
Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the ...
The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s ...
The United States cutting funding to Gavi, an organisation that provides vaccines to the world’s poorest countries, could result in more than a million … Continue reading US Cutting Gavi Vaccine Allia ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Jack Last died from a blood clot in his brain caused by a reaction to the Oxford AstraZeneca Covid-19 vaccination ...
The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...
One half of J&J’s treatment is Lazcluze, a pill that, like Astra’s Tagrisso, blocks a cancer-associated protein called EGFR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback